We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients.
- Authors
Oberic, Lucie; Vaillant, Willy; Hebraud, Benjamin; Recher, Christian; Suc, Etienne; Houyau, Philippe; Laurent, Guy; Ysebaert, Loic
- Abstract
Optimal treatment strategies are lacking in relapsed/refractory (R/R) chronic lymphocytic leukemia ( CLL). Gemcitabine has shown activity and acceptable safety profile in B-cell lymphomas. We present a retrospective case review of gemcitabine and alemtuzumab, every 21 d (for up to six courses) in 27 community-based patients with high-risk R/R CLL. Median age was 70 yr (44-83 yr), 55% patients had Binet stage C, deletion 17p (del(17p)) and/or deletion 11q (del(11q)) were found in 65% and 27%, bulky disease in 55.5%, and fludarabine-refractoriness in 48% of cases, respectively. Overall response rate was 63% (29.6% clinical CR and 33.4% PR). At a median follow-up of 31 months, median PFS and OS were 15.4 and 24 months. In multivariate analysis, median OS is influenced by prior lines of treatment = 3 and bulky disease. Combination of alemtuzumab and gemcitabine appears to be an active, easy to administrate treatment in routine practice, high-risk R/R CLL patients.
- Subjects
FLUDARABINE; CHRONIC lymphocytic leukemia treatment; CHRONIC lymphocytic leukemia; CHRONIC diseases; ALEMTUZUMAB; ANTINEOPLASTIC agents; HEMATOLOGIC malignancies; PATIENTS; THERAPEUTICS
- Publication
European Journal of Haematology, 2015, Vol 94, Issue 1, p37
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.12391